EVANSTON, Ill., Sept. 12 /PRNewswire-FirstCall/ --
Northfield Laboratories Inc. (Nasdaq: NFLD; NMS), a leading developer of an
oxygen-carrying blood substitute for trauma and elective surgery situations,
today encouraged its shareholders to participate in the Company's annual
meeting of shareholders to be held at 10:00 a.m. CDT on September 13, 2002.
Dr. Steven A. Gould, Northfield's Chairman and Chief Executive Office,
said, "Since assuming my duties as Northfield's Chief Executive Officer, I've
enjoyed speaking with many of the Company's shareholders and I am looking
forward to meeting many of them in person on Friday. For those shareholders
who are not able to attend," Dr. Gould indicated, "the meeting this year will
be broadcast live over the Internet and shareholders will also be able to
listen to the meeting by conference telephone."
Dr. Gould noted that management will provide a business presentation at
the meeting and that there will be a shareholder question and answer session
following the presentation. "We look forward to updating shareholders on
developments regarding Northfield's PolyHeme(TM) blood substitute product,"
Dr. Gould commented, "as well as our strategies for the future, including our
efforts to expand our senior management, raise additional capital, secure a
partnership with a major pharmaceutical company and increase Northfield's
profile in the scientific and investment communities."
The Internet webcast of Northfield's annual meeting may be accessed by
visiting Northfield's website at http://www.northfieldlabs.com or by logging on to
http://www.tfprn.com . Participants may also access the slides online and listen to
management's comments by dialing 800-452-1315 (domestic) or 706-634-7372
(international). Internet participants who wish to ask a question during the
live question and answer session will be able to click on an "ask a question"
link that will be available on both websites. Participants listening on the
phone will be able to forward a question to management through the operator.
A replay of the webcast will be available at http://www.northfieldlabs.com and
http://www.tfprn.com for 30 days following the event. The audio only replay will be
available until September 20 and may be accessed by dialing 800-642-1687
(domestic) or 706-645-9291, passcode 5496500.
Statements in this release that are not strictly historical are "forward-
looking" statements that are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks, which may cause the company's
actual results in the future to differ materially from expected results. These
risks include, among others: competition from other blood substitute products;
the company's ability to obtain regulatory approval to market PolyHeme
commercially; the company's and/or its representative's ability to
successfully market and sell PolyHeme; the company's ability to manufacture
PolyHeme in sufficient quantities; the company's ability to obtain an adequate
supply of raw materials; the company's ability to maintain intellectual
property protection for its proprietary product and to defend its existing
intellectual property rights from challenges by third parties; the
availability of capital to finance planned growth; and the extent to which the
hospitals and physicians using PolyHeme are able to obtain third-party
reimbursement, as described in the company's filings with the Securities and
Exchange Commission.
Visit the Northfield website at: http://www.northfieldlabs.com
SOURCE Northfield Laboratories, Inc.
 back to top
Related links:
http://www.northfieldlabs.com
http://www.tfprn.com
CONTACT:
Steven A. Gould, M.D., Chief Executive
Officer of Northfield Laboratories, +1-847-864-3500, or
Investors, Lisa Fortuna, +1-312-640-6779, or Media, Cindy Martin,
+1-312-640-6741, both of FRB Weber Shandwick
|
